Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22400168 | 0.88 | PDPK1 (0.34) | ALDH1A1LMNAHPGDTSHRMAPK1 | |
| SCHEMBL21725530 | 0.79 | NPC1 (0.33) | HSD17B10 | |
| SCHEMBL21725528 | 0.79 | PDPK1 (0.35) | ALDH1A1LMNAHPGDTSHRMAPK1 | |
| SCHEMBL21725527 | 0.69 | NPC1 (0.37) | ALDH1A1LMNAHPGDTSHRMAPK1 | |
| SCHEMBL16624809 | 0.69 | TSHR (0.39) | ALDH1A1LMNAHPGDTSHRMAPK1 | |
| SCHEMBL19425815 | 0.68 | PDPK1 (0.41) | ALDH1A1LMNAHPGDTSHRMAPK1 | |
| SCHEMBL20977931 | 0.67 | SELE (0.34) | ALDH1A1LMNAMAPK1 | |
| SCHEMBL26382098 | 0.67 | CA12 (0.30) | — | |
| SCHEMBL19294662 | 0.66 | TSHR (0.33) | TSHR | |
| SCHEMBL23717803 | 0.65 | PDPK1 (0.38) | ALDH1A1HPGDTSHRHSD17B10PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | ALDH1A1 2977/4885LMNA 4172/4885HPGD 1592/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | ALDH1A1 2977/4885LMNA 4172/4885HPGD 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.